The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies

Published:2017-12 Issue: Volume:61 Page:53-60
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Cortés Javier,Im Seock-Ah,Holgado Esther,Perez-Garcia Jose M.,Schmid Peter,Chavez-MacGregor Mariana

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference48 articles.

1. Mechanisms of endocrine resistance in breast cancer;Osborne;Annu Rev Med,2011

2. Estrogens andtheir receptors in breast cancer progression: a dual role in cancer proliferation and invasion;Platet;Crit Rev Oncol Hematol,2004

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast Cancer, version 2.2017. ; 2017 [accessed 04.09.17].

4. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3);Cardoso;Breast,2017

5. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline;Rugo;J Clin Oncol,2016

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models;2024-03-26

2. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia;Cancer Discovery;2024-01-03

3. Development and validation of reversed-phase-HPLC method for simultaneous quantification of fulvestrant and disulfiram in liposomes;Bioanalysis;2023-12

4. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer;Journal of Medicinal Chemistry;2023-10-05

5. PEGylated nanoassemblies composed of edelfosine and fulvestrant drugs: In vitro antiproliferative effect against breast cancer cells;Journal of Drug Delivery Science and Technology;2023-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3